Neurocrine Biosciences, Inc.

Report azionario NasdaqGS:NBIX

Capitalizzazione di mercato: US$15.6b

Neurocrine Biosciences Crescita futura

Criteri Future verificati 5/6

Neurocrine Biosciences prevede che gli utili e i ricavi cresceranno rispettivamente di 24% e 12% all'anno. Si prevede che l'EPS crescerà di 22.2% all'anno. Si prevede che il ritorno sul capitale proprio sarà di 21.3% in 3 anni.

Informazioni chiave

24.0%

Tasso di crescita degli utili

22.16%

Tasso di crescita dell'EPS

Biotechs crescita degli utili25.3%
Tasso di crescita dei ricavi12.0%
Rendimento futuro del capitale proprio21.32%
Copertura analitica

Good

Ultimo aggiornamento21 May 2026

Aggiornamenti recenti sulla crescita futura

Articolo di analisi • May 08

Neurocrine Biosciences, Inc. Just Recorded A 61% EPS Beat: Here's What Analysts Are Forecasting Next

Neurocrine Biosciences, Inc. ( NASDAQ:NBIX ) investors will be delighted, with the company turning in some strong...

Recent updates

Articolo di analisi • May 08

Neurocrine Biosciences, Inc. Just Recorded A 61% EPS Beat: Here's What Analysts Are Forecasting Next

Neurocrine Biosciences, Inc. ( NASDAQ:NBIX ) investors will be delighted, with the company turning in some strong...
Aggiornamento della narrazione • May 07

NBIX: Future Upside Will Depend On Execution Across Two Core Franchises

The updated analyst price target for Neurocrine Biosciences moves to $241.76 from $203.91, with analysts pointing to higher modeled revenue growth and slightly richer future P/E assumptions, partly balanced by a modestly lower profit margin outlook and a small change in the discount rate. Analyst Commentary Recent Street research on Neurocrine Biosciences shows a cluster of price target changes and fresh coverage that tilt bullish overall, even with a few modest trims.
Seeking Alpha • May 06

Neurocrine Biosciences: Core Business On Track, Soleno Deal Adds Risky Upside

Summary Neurocrine Biosciences delivered a strong Q1, with revenue up 42% and healthy growth in Ingrezza and Crenessity. Enhanced sales efforts could drive Ingrezza upside in 2H'26, while Crenessity has a long runway for patient adoption, particularly in adults. The $2.9 billion Soleno acquisition brings Vykat XR, a high-potential offering with clear commercial synergies but significant unknowns around long-term patient uptake and compliance. My fair value estimate for NBIX rises to just under $206/share, supported by multiyear upside in Ingrezza, Crenessity, and a promising, though long-dated, pipeline. I maintain a bullish stance on NBIX, seeing the market undervaluing core franchises and risk-adjusted pipeline upside despite tempered guidance. Read the full article on Seeking Alpha
Aggiornamento della narrazione • Apr 21

NBIX: Future Upside Will Hinge On Tardive Dyskinesia Franchise Execution

The updated analyst price target for Neurocrine Biosciences increases to $186.45 from $178.04. Analysts attribute the change to more supportive long-term earnings expectations and higher assumed future P/E multiples, even as they refine revenue growth and margin assumptions.
Aggiornamento della narrazione • Apr 07

NBIX: Mixed 2026 Guidance And Policy Risks Will Shape Future Returns

Analysts have made a small upward adjustment to the fair value estimate for Neurocrine Biosciences to about $140.54, reflecting updated price targets that weigh mixed revisions across the Street against generally constructive views on Ingrezza and Crenessity. Analyst Commentary Street research around Neurocrine Biosciences has been active, with a mix of supportive views on key assets like Ingrezza and Crenessity and a series of price target tweaks that pull in different directions.
Aggiornamento della narrazione • Mar 24

NBIX: Future Upside Will Depend On Crenessity Adoption And Pipeline Progress

Analysts have trimmed the blended price target for Neurocrine Biosciences slightly to about $178, reflecting modest tweaks to growth, discount rate and P/E assumptions, while incorporating mixed but generally constructive views on Ingrezza and Crenessity uptake from recent research updates. Analyst Commentary Street research on Neurocrine Biosciences has been active, with several firms adjusting price targets and models around recent earnings, updated guidance and new information on Ingrezza and Crenessity.
Aggiornamento della narrazione • Mar 09

NBIX: 2026 Guidance Execution And CAH Competition Will Shape Future Returns

Analysts have kept the fair value estimate for Neurocrine Biosciences steady at $140, while revising their models slightly to reflect updated revenue growth, margins, and P/E assumptions following recent earnings, guidance, and a mix of modest price target cuts and a fresh $160 Outperform initiation. Analyst Commentary Across recent research, you are seeing a mix of optimism around the pipeline and commercial assets along with a cluster of more cautious valuation resets.
Aggiornamento della narrazione • Feb 23

NBIX: Execution On 2026 Guidance And Competitive CAH Data Will Shape Outlook

Neurocrine Biosciences' updated analyst price target of $140.00, down from $169.00, reflects refreshed models after Q4 results and 2026 guidance, with analysts still pointing to Ingrezza and Crenessity as key drivers in their long term assumptions despite recent target trims across the Street. Analyst Commentary Street research around Neurocrine Biosciences has turned more mixed, with several bearish analysts trimming price targets following Q4 results and updated 2026 guidance, while a few others have made only modest upward adjustments.
Aggiornamento della narrazione • Feb 09

NBIX: Future Returns Will Hinge On Crenessity Execution And Pipeline Delivery

Analysts made a modest trim to their Neurocrine Biosciences price targets, generally landing around the high US$170s. Updated models reflect slightly more conservative revenue growth assumptions and a marginally higher discount rate, partly offset by steady margin expectations and supportive views on Crenessity and Ingrezza.
Aggiornamento della narrazione • Jan 24

NBIX: Future Revenue Will Depend On Execution Across Two Key Franchises

Analysts have raised their fair value estimate for Neurocrine Biosciences to about US$204 from US$192. This reflects updated assumptions that include slightly stronger revenue growth, higher profit margins and a lower future P/E multiple after recent Street research refined expectations for Ingrezza, Crenessity and competitor dynamics.
Aggiornamento della narrazione • Jan 10

NBIX: Commercial Execution And Pipeline Progress Will Drive Future Shareholder Returns

Analysts have raised their fair value estimate for Neurocrine Biosciences from about $177.92 to $179.66, reflecting updated models that incorporate recent price target revisions, current product performance, and expectations regarding future competition and commercial execution. Analyst Commentary Recent research updates show a mix of optimism and caution around Neurocrine Biosciences, with most price target moves clustering around the high $160s to mid $180s and reflecting updated models on current products, competitive developments in congenital adrenal hyperplasia, and spending to support commercial execution.
Aggiornamento della narrazione • Dec 17

NBIX: Advancing CNS Pipeline Readouts Will Drive Future Shareholder Returns

Analysts have modestly increased their average price target for Neurocrine Biosciences by about $3, to roughly $178, citing stronger than expected product performance, sustained Ingrezza growth momentum, and growing confidence in the company’s advancing pipeline despite potential IRA related pricing headwinds. Analyst Commentary Street research remains broadly constructive on Neurocrine, with multiple firms nudging price targets higher as they factor in stronger execution, commercial visibility for Ingrezza and Crenessity, and a maturing late stage pipeline.
Aggiornamento della narrazione • Dec 03

NBIX: Late-Stage CNS Pipeline Readouts Will Drive Future Shareholder Value

Analysts have nudged their blended price target for Neurocrine Biosciences modestly higher to the high $170s to low $180s range, reflecting stronger than expected Ingrezza and Crenessity performance, confidence in commercial execution ahead of IRA related headwinds, and growing optimism around the longer term pipeline. Analyst Commentary Bullish analysts largely frame the recent pullback as a mismatch between robust fundamentals and short term market sentiment, with multiple firms lifting price targets into the mid $160s to mid $190s range even as shares consolidated.
Aggiornamento della narrazione • Nov 19

NBIX: Late-Stage Pipeline Advancements Will Drive Shareholder Value Amid Industry Headwinds

Neurocrine Biosciences' analyst price target has increased modestly, up by $3 to $174. Analysts cite ongoing strong commercial performance, expanded sales force initiatives, and a robust late-stage pipeline as supporting factors for sustained growth potential.
Aggiornamento della narrazione • Nov 05

NBIX: Expanding Commercial Momentum And Pipeline Advances Will Drive Shareholder Value

The analyst price target for Neurocrine Biosciences has been raised from approximately $170 to $175 per share. This reflects analyst optimism about the company’s strong recent earnings, expanded sales efforts, and ongoing commercial and pipeline momentum.
Aggiornamento della narrazione • Oct 22

Analysts Boost Neurocrine Biosciences Price Target Citing Strong Revenue Outlook and Clinical Results

Analysts have raised their price target for Neurocrine Biosciences from $168.25 to $169.95. They cite stronger revenue outlooks for key products and supportive recent clinical trial data as the main reasons for this adjustment.
Seeking Alpha • Apr 22

Neurocrine Biosciences: Valbenazine As Adjunctive Therapy Could Stage Comeback In 2025

Summary Company's valbenazine shows promise as an adjunctive therapy for Schizophrenia, with phase 3 data expected in 2025, targeting patients unresponsive to antipsychotics. The company also anticipates phase 3 data for valbenazine in treating dyskinetic cerebral palsy in 2025, presenting another market opportunity. Neurocrine's financial health is robust, with $1.8 billion in cash and strong revenue growth from INGREZZA, which saw a 23% year-over-year increase in Q4 2024. The Schizophrenia market across the 7 major markets is expected to reach $17 billion by 2031. Read the full article on Seeking Alpha
Seeking Alpha • Apr 16

Neurocrine Biosciences: Recent Selloff Has Created A Potential Buying Opportunity

Summary Neurocrine Biosciences, Inc. has shown significant growth since its 1996 IPO, with a current stock price around $100, reflecting an 850% increase. Ingrezza is the flagship, >$2bn p.a. selling product. Despite a recent sell-off due to missed earnings targets and cautious 2025 guidance, Neurocrine's pipeline, including the newly approved Crenessity, may offer substantial growth potential. The company's robust portfolio and promising pipeline, including potential blockbusters like Crenessity and Ingrezza (valbenazine) label expansions, make it an intriguing contrarian buy opportunity. NBIX stock's valuation compared to peers suggests the recent market reaction may be overdone, positioning it as a potential takeover target with a valuation closer to $15 billion, in my view. Read the full article on Seeking Alpha
Nuova narrazione • Mar 20

Neurocrine Biosciences revenue will grow by 10% with Crenessity and Ingrezza sales if they can maintain the retail price.

Risks and uncertainties associated with Neurocrine Biosciences' business and finances in general, risks and uncertainties associated with the commercialization of INGREZZA and CRENESSITY.

Previsioni di crescita degli utili e dei ricavi

NasdaqGS:NBIX - Stime future degli analisti e dati finanziari passati (USD Millions )
DataRicaviUtiliFlusso di cassa liberoLiquidità dell'operazioneAvg. Numero di analisti
12/31/20285,0521,4391,7571,81714
12/31/20274,5141,1191,4051,41818
12/31/20263,76850193771819
3/31/20263,102669831864N/A
12/31/20252,861479749783N/A
9/30/20252,683428593637N/A
6/30/20252,510348529567N/A
3/31/20252,413306492530N/A
12/31/20242,355341557595N/A
9/30/20242,243386440476N/A
6/30/20242,120339495530N/A
3/31/20241,982370614645N/A
12/31/20231,887250362390N/A
9/30/20231,784191385409N/A
6/30/20231,673176281296N/A
3/31/20231,59964237255N/A
12/31/20221,489155323339N/A
9/30/20221,38958177201N/A
6/30/20221,29712133164N/A
3/31/20221,20871102129N/A
12/31/20211,13490233257N/A
9/30/20211,069445328347N/A
6/30/20211,032365251265N/A
3/31/20211,045402266280N/A
12/31/20201,046407218229N/A
9/30/20201,04293222232N/A
6/30/20201,006205337350N/A
3/31/2020887177283295N/A
12/31/201978837N/A147N/A
9/30/201967521N/A100N/A
6/30/201960518N/A71N/A
3/31/2019519-39N/A27N/A
12/31/201845121N/A101N/A
9/30/201841410N/A91N/A
6/30/2018323-52N/A13N/A
3/31/2018233-106N/A-55N/A
12/31/2017162-143N/A-94N/A
9/30/201767-194N/A-167N/A
6/30/20176-220N/A-188N/A
3/31/2017N/A-200N/A-154N/A
12/31/201615-141N/A-106N/A
9/30/201615-126N/A-90N/A
6/30/201615-123N/A-77N/A
3/31/201615-107N/A-49N/A
12/31/201520-89N/A-38N/A
9/30/201520-79N/A-38N/A
6/30/201520-60N/A-32N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: La crescita prevista degli utili di NBIX ( 24% all'anno) è superiore al tasso di risparmio ( 3.5% ).

Guadagni vs Mercato: Si prevede che gli utili di NBIX ( 24% all'anno) cresceranno più rapidamente del mercato US ( 16.8% all'anno).

Guadagni ad alta crescita: Si prevede che gli utili di NBIX cresceranno in modo significativo nei prossimi 3 anni.

Ricavi vs Mercato: Si prevede che il fatturato di NBIX ( 12% all'anno) crescerà più rapidamente del mercato US ( 11.7% all'anno).

Ricavi ad alta crescita: Si prevede che il fatturato di NBIX ( 12% all'anno) crescerà più lentamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Si prevede che il Return on Equity di NBIX sarà elevato tra 3 anni ( 21.3 %)

Scoprire le aziende in crescita

7D

1Y

7D

1Y

7D

1Y

Analisi aziendale e situazione dei dati finanziari

DatiUltimo aggiornamento (ora UTC)
Analisi dell'azienda2026/05/22 21:42
Prezzo dell'azione a fine giornata2026/05/22 00:00
Utili2026/03/31
Utili annuali2025/12/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

PacchettoDatiTempisticaEsempio Fonte USA *
Dati finanziari della società10 anni
  • Conto economico
  • Rendiconto finanziario
  • Bilancio
Stime di consenso degli analisti+3 anni
  • Previsioni finanziarie
  • Obiettivi di prezzo degli analisti
Prezzi di mercato30 anni
  • Prezzi delle azioni
  • Dividendi, scissioni e azioni
Proprietà10 anni
  • Top azionisti
  • Insider trading
Gestione10 anni
  • Team di leadership
  • Consiglio di amministrazione
Sviluppi principali10 anni
  • Annunci aziendali

* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.

Fonti analitiche

Neurocrine Biosciences, Inc. è coperta da 39 analisti. 19 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

AnalistaIstituzione
Martha FreitagArgus Research Company
Brian SkorneyBaird
Aydin HuseynovBenchmark Company